TY - JOUR
T1 - Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules
AU - Tamada, Koji
AU - Chen, Lieping
PY - 2006/4
Y1 - 2006/4
N2 - Molecules belonging to the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies have explosively expanded through the era of genomics and bioinformatics. Biological investigations of these molecules have explored their potency as attractive targets for cancer therapy. Anti-tumor mechanisms mediated by TNF superfamily molecules (TNFSF) could be classified into direct actions onto tumor cells and indirect effects through immune or non-immune components of tumor-bearing host. In this review, we focus on TRAIL, CD40, 4-1BB (CD137), and LIGHT as promising molecules to mediate powerful and selective anti-tumor responses, and summarize their unique effector mechanisms. In addition, optimal approaches to manipulate these molecules for cancer therapy are also discussed. We try to provide an insight into a role of TNFSF in cancer therapeutics and highlight each of their potency to be an important player in anti-cancer strategies.
AB - Molecules belonging to the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies have explosively expanded through the era of genomics and bioinformatics. Biological investigations of these molecules have explored their potency as attractive targets for cancer therapy. Anti-tumor mechanisms mediated by TNF superfamily molecules (TNFSF) could be classified into direct actions onto tumor cells and indirect effects through immune or non-immune components of tumor-bearing host. In this review, we focus on TRAIL, CD40, 4-1BB (CD137), and LIGHT as promising molecules to mediate powerful and selective anti-tumor responses, and summarize their unique effector mechanisms. In addition, optimal approaches to manipulate these molecules for cancer therapy are also discussed. We try to provide an insight into a role of TNFSF in cancer therapeutics and highlight each of their potency to be an important player in anti-cancer strategies.
UR - http://www.scopus.com/inward/record.url?scp=30444442143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30444442143&partnerID=8YFLogxK
U2 - 10.1007/s00262-005-0081-y
DO - 10.1007/s00262-005-0081-y
M3 - Article
C2 - 16187084
AN - SCOPUS:30444442143
SN - 0340-7004
VL - 55
SP - 355
EP - 362
JO - Cancer Immunology Immunotherapy
JF - Cancer Immunology Immunotherapy
IS - 4
ER -